940
J.J. Araya et al. / Phytochemistry 72 (2011) 935–941
acidic and neutral fractions were analyzed by LCMS and purified by
semi-preparative HPLC.
4.10. HPLC MSn analyses
The on-line HPLC/MSn analyses of extracts and fractions were
performed using an Agilent 1200 Series liquid chromatography
system coupled to a Agilent IonTrap LCMS 6310 mass spectrome-
ter. The positive ion ESI-MS experimental conditions were as fol-
lows: HV capillary voltage, 3.5 kV; drying temperature, 350 °C;
drying gas, 12.0 L/min; nebulizer, 15 psi; and capillary exit voltage,
124.8 V. The Frag Ampl was set to 1.0 V and the smart fragmenta-
tion function was used (Smart Frag Ampl was 30–200%). Targeted
analysis of zingerines was programmed as follows: (a) for [6]-zin-
gerine, isolation and fragmentation of ions m/z 411–413, then iso-
lation and detection of ion m/z 136.1; (b) for [8]-zingerine,
isolation and fragmentation of ions m/z 439–441, then isolation
and detection of ion m/z 136.1; (c) for [10]-zingerine, isolation
and fragmentation of ions m/z 467–469, then isolation and detec-
tion of ion m/z 136.1. The HPLC separations were done using an
4.4. Scale-up catch-and-release procedure
The methanolic rhizome extract (100 g) was suspended in
MeOH:H2O 2 L, 1:1 (v/v). A total of 200 g of prewashed Dowex
MAC-3 resin was added to the mixture and left stirring overnight.
The resin was then removed by filtration, washed several times
with pure MeOH (until the filtrate was clear) and the resin was fi-
nally left overnight stirring in 2% NH3 2% in MeOH (2 L). The resin
was removed by filtration, and the filtrate concentrated under re-
duced pressure to afford 1.9% basic fraction residue (1.9 g).
4.5. Isolation of zingerines
The basic fractions from the general catch-and-release protocol
were then separated by Sephadex LH-20 CC (100 g) using MeOH as
eluent to give 80 fractions (10 mL each) that were combined into
seven fractions (A–G) according to RP-TLC. Fraction F (210 mg)
was then purified using semipreparative HPLC with a linear gradi-
ent program of CH3CN and H2O water from 25:75 (v/v) (t = 0 min)
to 35:65 (t = 5 min), then 55:45 (t = 15 min), 100:0 (t = 25 min),
and finally recovery to 25:75 (t = 35 min). Compound 1 (18.2 mg,
tR = 14.7 min), compound 2 (5.2 mg, tR = 19.1 min), and compound
3 (4.8 mg, tR = 22.5 min) were obtained after removal of the mobile
phase under reduce pressure.
Agilent Eclipse XDB-C18 column (5
l
m, 4.6 ꢀ 150 mm) and the
flow rate was 1.0 mL/min (approx. 80 bar). The mobile phase was
a linear gradient of acetonitrile and water from 25:75 (v/v)
(t = 0 min) to 35:65 (t = 5 min), then 55:45 (t = 15 min), 100:0
(t = 25 min), and finally recovery to 25:75 (t = 35 min).
4.11. General synthesis of zingerines
A mixture of shogaol (0.33 mmol) and adenine (0.40 mmol,
1.2 eq.) and Cs2CO3 (5 mg) in MeOH:H2O 1:1 (15 mL) was stirred
at room temperature for 72 h. Then, organic solvent was removed
under reduced pressure and filtration, the reaction mixtures were
purified by semi preparative HPLC to afford the corresponding zin-
gerine. Accordingly, [6]-zingerine (42.7 mg), [8]-zingerine
(19.4 mg), and [10]-zingerine (19.4 mg) were obtained in 36%,
28%, and 30% yields, respectively.
4.6. Large scale isolation of shogaols
Pure [6]-, [8]-, and [10]-shogaol were isolated as described pre-
viously and the structures of the shogaols were confirmed by spec-
troscopic methods (Kim et al., 2008; Sang et al., 2009).
Acknowledgments
4.7. [6]-Zingerine (1)
The chemistry work was supported by NCCAM/ODS Grant
1R21AT004182-01A2 from the National Institutes of Health (NIH)
and the University of Kansas Center for Research project
2506014-910/099 to B.N.T., J.A. thanks LASPAU-Fulbright program
and the University of Costa Rica for financial support. J.A. also
thanks Kimberly Lovell for assistance during chiral HPLC separa-
tions. The contents are solely the responsibilities of the authors
and do not necessarily represent the official views of the NIH.
5-(6-Amino-9H-purin-9-yl)-1-(4-hydroxy-3-methoxy-
phenyl)decan-3-one; pale yellow oil;
½
a D25
ꢁ
= ꢂ0.004 (c. 0.03,
MeOH); UV (MeOH, c = 0.5 mM) kmax nm: 208, 262; IR
m
cmꢂ1
:
3326 (NAH), 3153 (NAH), 1711 (conj.>C@O), 1514 (C@C); 1H
NMR(CD3OD, 500 MHz) and 13C NMR (CD3OD, 133 MHz) see Table
1; ESIMS m/z 412.3 [M + H]+; ESIMS/MS m/z 136.1 [M + H-276.2];
HRMS m/z 412.2362 [M + H]+ (calc. for C22H30N5O2 412.2349).
Appendix A. Supplementary data
4.8. [8]-Zingerine (2)
Supplementary data associated with this article can be found, in
5-(6-Amino-9H-purin-9-yl)-1-(4-hydroxy-3-methoxy-
phenyl)dodecan-3-one; pale yellow oil; ½a 2D5
ꢁ
= ꢂ0.002 (c. 0.02,
MeOH); UV (MeOH, c = 0.5 mM) kmax nm: 208, 262; IR
m
cmꢂ1
:
References
3325 (NAH), 3153 (NAH), 1713 (conj.>C@O), 1513 (C@C); 1H
NMR (CD3OD, 500 MHz) and 13C NMR (CD3OD, 133 MHz) see Table
1; ESIMS m/z 440.3 [M + H]+; ESIMS/MS m/z 136.1 [M + H-304.2];
HRMS m/z 440.2695 [M + H]+ (calc. for C24H34N5O3 440.2662).
Afzal, M., Al-Hadidi, D., Menon, M., Pesek, J., Dhami, M.S.I., 2001. Ginger: an
ethomedical, chemical and pharmacological review. Drug Metabol. Drug
Interact. 18, 159–191.
Alexandratos, S.D., 2009. Ion-exchange resins: a retrospective from industrial and
engineering chemistry research. Ind. Eng. Chem. Res. 48, 388–398.
Ali, B.H., Blunden, G., Tanira, M.O., Nemmar, A., 2008. Some phytochemical,
pharmacological and toxicological properties of ginger (Zingiber officinale
Roscoe): a review of recent research. Food Chem. Toxicol. 46, 409–420.
Appenzeller, J., Mihci, G., Martin, M.T., Gallard, J.F., Menou, J.L., Boury-Esnalllt, N.,
Hooper, J., Petek, S., Chevalley, S., Valentin, A., Zaparucha, A., Al-Mourabit, A.,
Debitus, C., 2008. Agelasines J, K, and L from the Solomon Islands marine sponge
Agelas cf Mauritiana. J. Nat. Prod. 71, 1451–1454.
Araya, J.J., Montenegro, G., Mitscher, L.A., Timmermann, B.N., 2010. Application of
phase-trafficking methods to natural products research. J. Nat. Prod. 73, 1568–
1572.
Flynn, D.L., 1999. Phase-trafficking reagents and phase-switching strategies for
parallel synthesis. Med. Res. Rev. 19, 408–431.
4.9. [10]-Zingerine (3)
5-(6-Amino-9H-purin-9-yl)-1-(4-hydroxy-3-methoxy-
phenyl)tetradecan-3-one; pale yellow oil; ½a 2D5
ꢁ
= ꢂ0.001 (c. 0.02
MeOH); UV (MeOH, c = 0.5 mM) kmax nm: 208, 262; IR
m
cmꢂ1
:
3326 (NAH), 3152 (NAH), 1710 (conj.>C@O), 1513 (C@C); 1H
NMR (CD3OD, 500 MHz) and 13C NMR (CD3OD, 133 MHz) see Table
1; ESIMS m/z 468.3 [M + H]+; ESIMS/MS m/z 136.1 [M + H-332.2];
HRMS m/z 468.2921 [M + H]+ (calc. for C26H38N5O3 468.2975).